Evan Jerrold Barnes, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-bcr | 1 | 2020 | 20 | 0.740 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2022 | 434 | 0.730 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 250 | 0.660 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 689 | 0.600 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 1581 | 0.410 |
Why?
|
| Leukemia | 1 | 2020 | 1509 | 0.400 |
Why?
|
| Fatal Outcome | 1 | 2020 | 1851 | 0.130 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 1420 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 2649 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 1781 | 0.110 |
Why?
|
| Disease Management | 1 | 2020 | 2459 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 4803 | 0.080 |
Why?
|
| Cell Line | 1 | 2022 | 15993 | 0.080 |
Why?
|
| Biopsy | 1 | 2020 | 6750 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8637 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 5170 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5532 | 0.070 |
Why?
|
| Mutation | 1 | 2022 | 29777 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 63042 | 0.030 |
Why?
|
| Humans | 2 | 2022 | 743811 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 213241 | 0.020 |
Why?
|
| Male | 1 | 2020 | 349776 | 0.010 |
Why?
|
| Female | 1 | 2020 | 380020 | 0.010 |
Why?
|